Skip to content

Gebruik de knoppen om de artikels, publicaties en presentaties van deze auteur te raadplegen.

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Blood 2022 Apr 14;139(15):2338-2346. doi: 10.1182/blood.2021013526. -PMID: 34936697 DOI: 10.1182/blood.2021013526

High total metabolic tumor volume at baseline predicts survival independent of response to therapy.

Blood. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526.PMID: 31978225 Free PMC article. Clinical Trial.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2020 Apr;189(1):84-96. doi: 10.1111/bjh.16300. Epub 2019 Nov 8.PMID: 31702836 Free PMC article.

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2020 May;105(5):1306-1316. doi: 10.3324/haematol.2019.222612. Epub 2019 Aug 1.PMID: 31371409 Free PMC article

Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases.

Belgian journal of hematology volume 10 issue 2 march 2019 p 69-79.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300. PMID: 31702836

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. PMID: 31371409

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. PMID: 31296423

Highlights in lymphoma.

Belgian Journal of Hematology. 2018 Feb; 9(1): 14-18.

Hodgkin’s lymphoma: Belgian Hematology Society guidelines in diagnosis, treatment and follow-up.

Belgian Journal of Hematology. 2018; 9; 214-224.

Neuropathie, longinfecties en andere ernstige complicaties bij multiple myeloom en Waldenström.

T-cell lymphoma.

26/03/2022
Brussel

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study.

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”.

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial.

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN WALDENSTRÖM’S MACROGLOBULINEMIA (WM) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP.

Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up.

EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3-YEAR FOLLOW-UP.

06/09/2021
Poster at virtual EHA 2021

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study.

01/01/2020
ASH 2020

Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP.

06/12/2020
Poster at ASH;

TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT.

01/01/2019
EHA Library. Depreter B. 06/14/19; 265994; PF204. Poster at EHA 2019.

Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study.

01/01/2018
Poster At ASH 2018

Galapagos project: samenwerking met reumatologie: Bloody issues in RA. Hematologische problemen bij patiënten met reumatoïde arthritis.

Urgenties in de hematologie.

Young hematology education: How to onboard a CLL patient in first line treatment?

Waldenström’s macroglobulinemia and renal insufficiency: a case report.

Clinical Outcomes with Single-Agent ibrutinib for relapsed/refractory mantle cell lymphoma: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Effectiveness and safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

20th Post-ASH Meeting.

12/01/2018
Brussel
Back To Top